Special Guest · 8:00–8:15 AM PT
?
Special guest
ACA presentation by Patrick Gouhin
Chief Executive Officer
Angel Capital Association
Tel: 913-894-4700 X 1
pgouhin@angelcapitalassociation.org
Pitches · 8:15–9:30 AM PT
GeniPhys
Andrew Eibling, CEO · andyeibling@geniphys.com
↩ Previously pitched at Medical Mondays · October 28, 2024
Restorative biomaterial platform that supports tissue regeneration without inflammation.
Round
$5.5 million Priced Round @ $10 million
Closed
$3 million
FDA milestone
510(k) cleared (June 2025) for first indication (wound care)
Other groups in round
Elevate Ventures
DD package
Elevate Ventures has a diligence packet they are willing to share
Traction: MOU in place with commercial partner for wound care
Crimson Scientific
Michael Cetta, MD, CEO · michael@crimsonscientific.com
We are modernizing the EKG to make it fast, accurate and simple.
Round
$3,000,000 Undecided @ 12,000,000 post
Closed
0
FDA milestone
QMS in place. Regulatory/Quality consulting secured.
FDA timeline
12 months to submission
Other groups in round
our pre-seed round had participation from Baxter Healthcare, Endeavor Health and mHUB Ventures.
DD package
no
Traction: LOI from Who We Play For
What they're looking for: business strategy, KOL access, funding
Liquet Medical
John Schindler, CEO · j.schindler@liquetmedical.com
Liquet Medical is developing the Versus™ Catheter, a pulmonary artery infusion and monitoring system designed to enable more precise delivery of thrombolytic drugs while providing real-time pulmonary artery pressure monitoring. The system allows physicians to infuse medication into both lungs simultaneously while observing hemodynamic response during therapy. This approach is intended to help clinicians better understand how patients are responding to therapy and optimize treatment decisions during catheter-directed procedures.
Round
$1.5M in Convertible Notes Convertible Note @ $12M cap on the notes
Closed
$275K closed with a further $500K additional committed
FDA milestone
2 products FDA 510(k) cleared and we are now moving into initial clinical work
FDA timeline
Completed
Other groups in round
VVP, CAV Angels, Rowan Innovation Fund, Alamo Angels, 757 Angels
DD package
This is an insider-led round, previous DD has been conducted yet is dated
Traction: LOS from 10 physicians/institutions, multiple clinical sites moving thru IRB process for clinical use
What they're looking for: KOL & Strategics connections are always welcome where possible - thank you!